ABCL – abcellera biologics inc. - common shares (US:NASDAQ)
Stock Stats
News
AbCellera to Participate at Upcoming Investor Conferences in March [Yahoo! Finance]
AbCellera to Participate at Upcoming Investor Conferences in March
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
AbCellera Biologics Inc. (NASDAQ: ABCL) had its price target lowered by analysts at KeyCorp from $5.00 to $4.00. They now have an "overweight" rating on the stock.
Form 4 AbCellera Biologics Inc. For: Jan 01 Filed by: Stimart Tryn
Form 4 AbCellera Biologics Inc. For: Jan 01 Filed by: Lecault Veronique
Form 4 AbCellera Biologics Inc. For: Jan 01 Filed by: Booth Andrew
Form 4 AbCellera Biologics Inc. For: Jan 01 Filed by: Hansen Carl L. G.
Form 4 AbCellera Biologics Inc. For: Dec 04 Filed by: Thermopylae Holdings Ltd.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.